Dr. Josh Schiffman, Medical Director, High Risk Pediatric Cancer Clinic, Huntsman Cancer Institute, University of Utah
The challenges of formalin-fixed, paraffin-embedded (FFPE) samples hinder many cancer researchers looking to unlock archival samples with retrospective clinical data. Standard array CGH methods result in high sample failure rates and low dynamic range, require a high amount of input DNA, and provide only relative copy number information. Furthermore, once molecular data has been extracted from the FFPE samples, identification of genomic aberrations and uncovering the biological significance of these findings pose another significant challenge to cancer researcher. In this presentation, we will provide some example cases where OncoScan™ offered by Affymterix, Inc. coupled with BioDiscovery’s Nexus Copy Number™ software has enabled significant discoveries in cancer research. After a general review of the Molecular Inversion Probe (MIP) technology used by OncoScan™, we will describe how this novel microarray platform has been linked with the powerful and intuitive Nexus Copy Number™ software to allow clinically relevant discoveries in Acute Lymphoblastic Leukemia (ALL), Burkitt Lymphoma, and Ewing Sarcoma. An interactive question and answer session will be provided at the end of the presentation.
This webinar is geared towards cancer researchers interested in unlocking the potential of their FFPE samples using OncoScan sample processing and BioDiscovery Nexus data analysis to